Paper37726283
mRNA vaccines in disease prevention and treatment.
Zhang G and 4 others. Signal Transduct Target Ther, 2023. Cited by 202 papers, by iCite.
Cite this record
ConductScience Library. mRNA vaccines in disease prevention and treatment. Papers, record 37726283. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/37726283
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics6
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| COVID-19 | Major topic |
| Humans | |
| Prospective Studies | |
| Retrospective Studies | |
| Adjuvants, Immunologic | |
| mRNA Vaccines |
Source PubMed
References254
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 34794169 | Optimization of non-coding regions for a non-modified mRNA COVID-19 vaccine. | Nature | 2022 | https://conductscience.org/library/papers/34794169 | PubMed |
| 2 | 32728218 | An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma. | Nature | 2020 | https://conductscience.org/library/papers/32728218 | PubMed |
| 3 | 32591862 | A randomized controlled phase II clinical trial on mRNA electroporated autologous monocyte-derived dendritic cells (TriMixDC-MEL) as adjuvant treatment for stage III/IV melanoma patients who are disease-free following the resection of macrometastases. | Cancer Immunol Immunother | 2020 | https://conductscience.org/library/papers/32591862 | PubMed |
| 4 | 16947019 | T cell responses in melanoma patients after vaccination with tumor-mRNA transfected dendritic cells. | Cancer Immunol Immunother | 2007 | https://conductscience.org/library/papers/16947019 | PubMed |
| 5 | 30518847 | Structural and molecular mechanisms for the control of eukaryotic 5'-3' mRNA decay. | Nat Struct Mol Biol | 2018 | https://conductscience.org/library/papers/30518847 | PubMed |
| 6 | 29456015 | Multi-antigenic human cytomegalovirus mRNA vaccines that elicit potent humoral and cell-mediated immunity. | Vaccine | 2018 | https://conductscience.org/library/papers/29456015 | PubMed |
| 7 | 33685460 | Identification of tumor antigens and immune subtypes of cholangiocarcinoma for mRNA vaccine development. | Mol Cancer | 2021 | https://conductscience.org/library/papers/33685460 | PubMed |
| 8 | 8760800 | Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. | J Exp Med | 1996 | https://conductscience.org/library/papers/8760800 | PubMed |
| 9 | 32153780 | Toll-like receptor 7/8-matured RNA-transduced dendritic cells as post-remission therapy in acute myeloid leukaemia: results of a phase I trial. | Clin Transl Immunology | 2020 | https://conductscience.org/library/papers/32153780 | PubMed |
| 10 | 23921513 | A novel, disruptive vaccination technology: self-adjuvanted RNActive(®) vaccines. | Hum Vaccin Immunother | 2013 | https://conductscience.org/library/papers/23921513 | PubMed |
| 11 | 25263094 | The ReNAissanCe of mRNA-based cancer therapy. | Expert Rev Vaccines | 2015 | https://conductscience.org/library/papers/25263094 | PubMed |
| 12 | 29567706 | Personalized vaccines for cancer immunotherapy. | Science | 2018 | https://conductscience.org/library/papers/29567706 | PubMed |
| 13 | 35339668 | Recent advances of nanodrug delivery system in the treatment of hematologic malignancies. | Semin Cancer Biol | 2022 | https://conductscience.org/library/papers/35339668 | PubMed |
| 14 | 30803823 | mRNA as a Transformative Technology for Vaccine Development to Control Infectious Diseases. | Mol Ther | 2019 | https://conductscience.org/library/papers/30803823 | PubMed |
| 15 | 26321183 | mRNA: Fulfilling the Promise of Gene Therapy. | Mol Ther | 2015 | https://conductscience.org/library/papers/26321183 | PubMed |
| 16 | 30504800 | Modified VEGF-A mRNA induces sustained multifaceted microvascular response and accelerates diabetic wound healing. | Sci Rep | 2018 | https://conductscience.org/library/papers/30504800 | PubMed |
| 17 | 18797453 | Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. | Mol Ther | 2008 | https://conductscience.org/library/papers/18797453 | PubMed |
| 18 | 28527533 | Global, Regional, and National Burden of Cardiovascular Diseases for 10 Causes, 1990 to 2015. | J Am Coll Cardiol | 2017 | https://conductscience.org/library/papers/28527533 | PubMed |
| 19 | 35264324 | Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational study. | BMJ | 2022 | https://conductscience.org/library/papers/35264324 | PubMed |
| 20 | 8903508 | The eIF-2alpha kinases and the control of protein synthesis. | FASEB J | 1996 | https://conductscience.org/library/papers/8903508 | PubMed |
Cited by141
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 202 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42958362 | Neoantigen nanovaccines for cancer immunotherapy: design strategies, translational bottlenecks, and clinical prospects. | J Nanobiotechnology | 2026 | https://conductscience.org/library/papers/42958362 | PubMed |
| 42866351 | Exploring the potential of mRNA vaccines in combatting communicable and non-communicable diseases in low-income and lower-middle-income countries. | Ann Med Surg (Lond) | 2026 | https://conductscience.org/library/papers/42866351 | PubMed |
| 42804114 | mRNA lipid nanoparticle vaccines: current status, challenges and future prospects. | Mol Biomed | 2026 | https://conductscience.org/library/papers/42804114 | PubMed |
| 42618806 | Enhanced antitumor immunity of mRNA vaccines by bioorthogonal-like delayed activation of exogeneous STING. | Nat Biotechnol | 2026 | https://conductscience.org/library/papers/42618806 | PubMed |
| 42614300 | From pathogen defence to precision health infrastructure: mRNA vaccines beyond infectious disease in preventive health, chronic disease management, and population wellbeing. | Front Bioeng Biotechnol | 2026 | https://conductscience.org/library/papers/42614300 | PubMed |
| 42605164 | Immunological Evaluation of mRNA-LNP Vaccines Targeting Conserved S2 and NSP3 Domains of SARS-CoV-2. | Biotechnol J | 2026 | https://conductscience.org/library/papers/42605164 | PubMed |
| 42599953 | Design of an immunogen containing multidimensionally conserved and immunogenic parts of the HIV proteome. | PLoS Comput Biol | 2026 | https://conductscience.org/library/papers/42599953 | PubMed |
| 42565117 | Beyond the genetic code: orchestrating epigenetic and immune landscapes with multivalent mRNA-exosome vaccines. | Precis Clin Med | 2026 | https://conductscience.org/library/papers/42565117 | PubMed |
| 42523811 | Targeting dengue through mucosal vaccination: the potential of NS1 and bacterial spore-based delivery platforms. | Front Immunol | 2026 | https://conductscience.org/library/papers/42523811 | PubMed |
| 42482120 | RNARL: reinforcement learning-driven unified generative framework for multi-objective RNA codon design. | Genome Biol | 2026 | https://conductscience.org/library/papers/42482120 | PubMed |
| 42472832 | RNA modifications in cancer: regulators of tumor evolution and therapeutic response. | Mol Cancer | 2026 | https://conductscience.org/library/papers/42472832 | PubMed |
| 42424000 | Immunotherapeutic modalities for combating multidrug-resistant bacteria: therapeutic promises of antibodies and next-generation vaccines. | Naunyn Schmiedebergs Arch Pharmacol | 2026 | https://conductscience.org/library/papers/42424000 | PubMed |
| 42350438 | Next-generation mRNA vaccines: strategies to overcome stability challenges. | NPJ Vaccines | 2026 | https://conductscience.org/library/papers/42350438 | PubMed |
| 42342874 | Immunological mechanisms of mRNA vaccines for infectious diseases. | Nature | 2026 | https://conductscience.org/library/papers/42342874 | PubMed |
| 42199419 | Emerging frontiers in glioma therapy: the evolving role of glioma vaccines. | Front Immunol | 2026 | https://conductscience.org/library/papers/42199419 | PubMed |
| 42188740 | Nucleoside Modifications and Poly(A) Tail Length Greatly Influence Protein Expression from In Vitro-Transcribed mRNA in a Salmonid Cell Line. | Vaccines (Basel) | 2026 | https://conductscience.org/library/papers/42188740 | PubMed |
| 42140901 | A nanobody-based proteolysis-targeting chimera offers broad-spectrum protection against diverse influenza virus infections. | Signal Transduct Target Ther | 2026 | https://conductscience.org/library/papers/42140901 | PubMed |
| 42123607 | Sulforaphane-Activated Functional Nucleic Acids for Cancer Therapy: Mechanisms, Delivery Strategies, and Nanomedicine Advances. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42123607 | PubMed |
| 42095075 | Single-cell transcriptomics reveal altered B cell responses and T cell senescence in geriatric non-responders to COVID-19 mRNA vaccination. | iScience | 2026 | https://conductscience.org/library/papers/42095075 | PubMed |
| 42087213 | Personalized immunotherapy in HCC: synthesis, delivery, and clinical progress of mRNA-based vaccines. | Cancer Cell Int | 2026 | https://conductscience.org/library/papers/42087213 | PubMed |
Genes88
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/37726283
GET https://conductscience.org/api/papers/v1/37726283/references?page=2